[1]谭军华,金小掺,冷雪姣.糖皮质激素联合他克莫司对肾病综合征患者肾功能及炎症因子水平的影响[J].医学信息,2023,36(20):129-132.[doi:10.3969/j.issn.1006-1959.2023.20.025]
　TAN Jun-hua,JIN Xiao-shan,LENG Xue-jiao.Effect of Glucocorticoid Combined with Tacrolimus on Renal Function and Inflammatory Factor Levels in Patients with Nephrotic Syndrome[J].Journal of Medical Information,2023,36(20):129-132.[doi:10.3969/j.issn.1006-1959.2023.20.025]
点击复制

糖皮质激素联合他克莫司对肾病综合征患者肾功能及炎症因子水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年20期
页码:
129-132
栏目:
论著
出版日期:
2023-10-15

文章信息/Info

Title:
Effect of Glucocorticoid Combined with Tacrolimus on Renal Function and Inflammatory Factor Levels in Patients with Nephrotic Syndrome
文章编号:
1006-1959（2023）20-0129-04
作者:
谭军华; 金小掺; 冷雪姣
（丹阳市人民医院肾脏内科，江苏 丹阳 212300）
Author(s):
TAN Jun-hua; JIN Xiao-shan; LENG Xue-jiao
(Department of Nephrology,Danyang People’s Hospital,Danyang 212300,Jiangsu,China)
关键词:
糖皮质激素; 他克莫司; 肾病综合征; 肾功能; 炎症因子
Keywords:
Glucocorticoid; Tacrolimus; Nephrotic syndrome; Renal function; Inflammatory cytokines
分类号:
R692
DOI:
10.3969/j.issn.1006-1959.2023.20.025
文献标志码:
A
摘要:
目的 观察糖皮质激素联合他克莫司对肾病综合征患者肾功能及炎症因子水平的影响。方法 选取2018年1月-2022年6月我院诊治的62例肾病综合征患者为研究对象，采用随机数字表法分为对照组和观察组，各31例。对照组予以泼尼松治疗，观察组在对照组治疗基础上联合他克莫司治疗，比较两组临床疗效、肾功能指标[24h尿蛋白、血尿素氮（BUN）、血肌酐（SCr）]、炎症因子水平[白细胞（WBC）、超敏-c反应蛋白（hs-CRP）、白细胞介素-6（IL-6）]、不良反应发生情况、生活质量水平。结果 观察组总有效率为93.55%，高于对照组的80.65%（P＜0.05）；两组治疗后24 h尿蛋白、BUN、SCr水平低于治疗前，且观察组低于对照组（P＜0.05）；两组治疗后WBC高于治疗前，hs-CRP、IL-6水平低于治疗前，且观察组WBC高于对照组，hs-CRP、IL-6水平低于对照组（P＜0.05）；观察组不良反应总发生率与对照组比较，差异无统计学意义（P＞0.05）；两组治疗后生活质量评分高于治疗前，且观察组高于对照组（P＜0.05）。结论 糖皮质激素联合他克莫司治疗肾病综合征的效果确切，可改善肾功能，降低炎症因子水平，提高生活质量，且不增加不良反应发生几率。
Abstract:
Objective To observe the effect of glucocorticoid combined with tacrolimus on renal function and inflammatory factors in patients with nephrotic syndrome.Methods A total of 62 patients with nephrotic syndrome diagnosed and treated in our hospital from January 2018 to June 2022 were selected as the research objects. They were divided into control group and observation group by random number table method, with 31 patients in each group. The control group was treated with prednisone, and the observation group was treated with tacrolimus on the basis of the control group. The clinical efficacy, renal function indexes [24 h urine protein, blood urea nitrogen (BUN), serum creatinine (SCr)], inflammatory factor levels [white blood cell (WBC), hypersensitive-c-reactive protein (hs-CRP), interleukin-6 (IL-6)], adverse reactions and quality of life were compared between the two groups.Results The total effective rate of the observation group was 93.55%, which was higher than 80.65% of the control group (P<0.05). The levels of 24 h urine protein, BUN and SCr in the two groups after treatment were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). After treatment, the WBC of the two groups was higher than that before treatment, the levels of hs-CRP and IL-6 were lower than those before treatment, while the WBC of the observation group was higher than that of the control group, the levels of hs-CRP and IL-6 were lower than those of the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the observation group and the control group (P>0.05). The quality of life scores of the two groups after treatment were higher than those before treatment, and the observation group was higher than the control group (P<0.05).Conclusion Glucocorticoid combined with tacrolimus is effective in the treatment of nephrotic syndrome, which can improve renal function, reduce the level of inflammatory factors, improve the quality of life, and do not increase the incidence of adverse reactions.

参考文献/References:

[1]刘梦堃,回亚男,刘斌.大黄虫丸联合他克莫司治疗肾病综合征的临床研究[J].现代药物与临床,2020,35(7):1355-1358.[2]朱莉,邵维斌,夏春英,等.环磷酰胺联合糖皮质激素对原发性肾病综合征患者肾功能和血脂的影响[J].贵州医科大学学报,2018,43(11):1336-1339. [3]Makoto Y,Masahiko A,Takayuki K,et al.Urinary protein and re nal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan[J].Renal Failure,2018,40(1):435-441．[4]Trautmann A,Vivarelli M,Samuel S,et al.IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome[J].Pediatr Nephrol,2020,35(8):1529-1561.[5]孔令强,李勋,刘梦欣.他克莫司联合醋酸泼尼松治疗原发性肾 病综合征的临床疗效及对外周血Th17和血脂水平的影响[J].检验医学与临床,2020,17(17):2547-2549. [6]陈国华,陈秋如,曾聪灵,等.他克莫司与环磷酰胺分别联合糖皮质激素治疗儿童难治性肾病综合征效果观察[J].白求恩医学杂志,2019,17(2):120-122.[7]Chen X,Wang DD,Xu H,et al.Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule[J].Xenobiotica,2020,50(5):606-613．[8]王元真,赵汉儒,林丽娟.黄芪当归合剂联合他克莫司对难治性肾病综合征患者免疫功能及肾功能的影响[J].上海中医药杂志,2019,52(6):58-60,74.[9]赵鹤新.益气固肾方联合他克莫司对肾病综合征患者SOCS、免疫球蛋白及补体的影响分析[J].中国地方病防治杂志,2019,34(4):419,421. [10]田明,刘翠华,厉洪江,等.他克莫司治疗儿童难治性肾病综合征的疗效观察及对血液生化指标的影响[J].实用医院临床杂志,2018,15(4):86-89.[11]孙龙春.他克莫司联合雷公藤多苷对肾病综合征患者NF-κB与炎症细胞因子的影响[J].上海医药,2017,37(19):38-40,50.[12]徐晓琴,胡晓娟,周洪,等.雷公藤多苷联合糖皮质激素治疗PNS患者的疗效[J].中国卫生标准管理,2020,11(4):108-110.[13]王丽艳,边俊梅,倪文昌.他克莫司联合小剂量西罗莫司治疗儿童激素耐药型肾病综合征的临床疗效与安全性研究[J].临床肾脏病杂志,2019,19(7):493-497.[14]Zou H,Jiang F,Xu G.Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy[J].Ren Fail,2019,41(1):673-681.[15]赵丽平,刘连升,胡岗,等.氯沙坦钾片联合环磷酰胺注射剂治疗局灶节段性肾小球硬化症的临床研究[J]. 中国临床药理学杂志,2019,35(7):630-632.[16]张欣,李青梅,马青山,等.他克莫司联合低剂量激素治疗儿童难治性肾病综合征临床疗效(附16例报告)[J].吉林大学学报(医学版),2018,44(5):172-176.[17]Linhares ND,Arantes RR,Araujo SA,et al.Nephrotic syndrome and adrenal insufficiency caused by a variant in SGPL1[J].Clin Kidney J,2018,11(4):462-467.[18]张新阳.利湿化瘀汤联合氯沙坦钾及雷公藤多苷治疗IgA肾病的临床效果[J].中外医学研究,2019,17(19):34-36.[19]Basu B,Sander A,Roy B,et al.Efficacy of rituximab vs tacrolimus in pediatric corticosteroid dependent nephrotic syndrome a randomized clinical trial[J].JAMA Pediatr,2018,172(8):757-764.[20]王元元,何华琼.雷公藤多苷片联合甲泼尼龙脉冲治疗儿童系统性红斑狼疮临床研究[J].湖北医药学院学报,2019,38(3):226-230.[21]张永芳,徐江维.大剂量环磷酰胺治疗小儿难治性肾病综合征的临床疗效研究[J].陕西医学杂志,2018,47(1):105-107.[22]徐佶,颜思诗,吴广宇,等.他克莫司联合半剂量糖皮质激素治疗表现为肾病综合征的特发性膜性肾病临床疗效与安全性分析[J].中国药物与临床,2019,19(15):2610-2611.[23]王莉,金明,黄俊波,等.他克莫司联合糖皮质激素对难治性肾病综合征患者肝肾功能、糖脂代谢及不良反应的影响[J].解放军医药杂志,2019,31(2):90-93.[24]陈琪,闵晶晶,戴竹泉,等.他克莫司单药治疗特发性膜性肾病的临床疗效观察[J].广东医学,2019,40(19):2774-2777,2781.

相似文献/References:

[1]钟时嘉.亚急性甲状腺炎的临床分析[J].医学信息,2018,31(01):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
　ZHONG Shi-jia.Clinical Analysis of Subacute Thyroiditis[J].Journal of Medical Information,2018,31(20):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
[2]唐培渊,宋俊峰,秦克乐,等.难治性特发性血小板减少性紫癜的治疗进展[J].医学信息,2018,31(05):42.[doi:10.3969/j.issn.1006-1959.2018.05.016]
　TANG Pei-yuan,SONG Jun-feng,QIN Ke-le,et al.Progress in Treatment of Refractory Idiopathic Thrombocytopenic Purpura[J].Journal of Medical Information,2018,31(20):42.[doi:10.3969/j.issn.1006-1959.2018.05.016]
[3]苗艳茹.甲巯咪唑与糖皮质激素联合治疗甲状腺功能亢进症合并症的效果分析[J].医学信息,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
　MIAO Yan-ru.Analysis of Effects of Methimazole and Glucocorticoids on Complications of Hyperthyroidism[J].Journal of Medical Information,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
[4]康 凯,郑继伟,王 闰.糖皮质激素治疗甲亢伴浸润性突眼的疗效分析[J].医学信息,2018,31(08):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
　KANG Kai,ZHENG Ji-wei,WANG Run.Efficacy of Glucocorticoids in the Treatment of Hyperthyroidism with Infiltrating Exophthalmos[J].Journal of Medical Information,2018,31(20):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
[5]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
　ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Journal of Medical Information,2018,31(20):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[6]刘广涛,关凤军,董 晨.原发性肾病综合征患儿肾组织P-gp170蛋白和mRNA表达与临床病理及预后的关系[J].医学信息,2018,31(21):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
　LIU Guang-tao,GUAN Feng-jun,DONG Chen.Relationship between the Expression of p-gp170 Protein and mRNA in Renal Tissue of Children with Primary Nephrotic Syndrome and Clinical Pathology and Prognosis[J].Journal of Medical Information,2018,31(20):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
[7]陈晓霞,唐 勇,胡 庆,等.吗替麦考酚酯联合糖皮质激素治疗特发性膜性肾病的疗效观察[J].医学信息,2018,31(22):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
　CHEN Xiao-xia,TANG Yong,HU Qing,et al.Therapeutic Effect of Mycophenolate Mofetil Combined with Glucocorticoid on Idiopathic Membranous Nephropathy[J].Journal of Medical Information,2018,31(20):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
[8]高 鹏,高 浩,燕 飞.坏疽性脓皮病1例[J].医学信息,2019,32(01):191.[doi:10.3969/j.issn.1006-1959.2019.01.063]
[9]马艳艳,刘建军.肌无力危象的治疗研究进展[J].医学信息,2019,32(06):45.[doi:10.3969/j.issn.1006-1959.2019.06.016]
　MA Yan-yan,LIU Jian-jun.Progress in the Treatment of Myasthenia Crisis[J].Journal of Medical Information,2019,32(20):45.[doi:10.3969/j.issn.1006-1959.2019.06.016]
[10]谢卫强,巩 栋,高明暄,等.关节病性银屑病伴髋关节结核1例[J].医学信息,2019,32(07):189.[doi:10.3969/j.issn.1006-1959.2019.07.062]

更新日期/Last Update: 1900-01-01